Infection and malignancy after pediatric heart transplantation: The role of induction therapy

Journal of Heart and Lung Transplantation

Volumn 30, Issue 3, 2011, Pages 299-308

  Gajarski, Robert J ^a   Blume, Elizabeth D ^b   Urschel, Simon ^c   Schechtman, Kenneth ^d   Zheng, Jie ^d   West, Lori J ^c   Altamirano, Louis ^c   Miyamoto, Shelley ^e   Naftel, David C ^f   Kirklin, James K ^f   Zamberlan, Mary C ^a   Canter, Charles E ^g  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHILDREN S HOSPITAL COLORADO   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; DACLIZUMAB; GANCICLOVIR; OKT 3; THYMOCYTE ANTIBODY;

ARTICLE; BACTERIAL INFECTION; CARDIAC GRAFT REJECTION; CHILD; COLON CARCINOMA; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; FEMALE; HEART TRANSPLANTATION; HUMAN; KIDNEY CARCINOMA; LIVER CARCINOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OUTCOME ASSESSMENT; PEDIATRIC SURGERY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTOZOAL INFECTION; RISK ASSESSMENT; SARCOMA; VIRUS INFECTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MYCOSES; PROSPECTIVE STUDIES; RISK; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 79551684833     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2010.09.005     Document Type: Article

References (44)

1. R. Kirk, L.B. Edwards, P. Aurora, D.O. Taylor, J. Christie, F. Dobbels, A.Y. Kucheryavaya, A.O. Rahmel, and M.I. Hertz Registry of the International society for Heart and Lung Transplantation: eleventh official pediatric heart transplantation report2008 J Heart Lung Transplant 27 2008 970 977
2. T.P. Singh, L.B. Edwards, R. Kirk, and M.M. Boucek Era effect on post-transplant survival adjusted baseline risk factors in pediatric heart transplantation J Heart Lung Transplant 28 2009 1285 1291
3. M.D. Denton, C.C. Magee, and M.H. Sayegh Immunosuppressive strategies in transplantation Lancet 353 1999 1083 1091
4. R.J. Boucek, D. Naftel, M.M. Boucek PHTS Induction immunotherapy in pediatric heart transplant recipients: a multicenter study J Heart Lung Transplant 18 1999 460 469
5. F. Parisi, H. Danesi, C. Squitieri, L. Di Chiara, L. Rav, and R.M. Di Donato Thymoglobuline use in pediatric heart transplantation J Heart Lung Transplant 22 2003 591 593
6. S. Di Filippo, P. Boissonnat, and F. Sassolas Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation Transplantation 75 2003 354 358
7. V.A. Starnes, P.E. Oyer, E.B. Stinson, J.R. Dein, and N.E. Shumway Prophylactic OKT3 used as induction therapy for heart transplantation Circulation 80 suppl III 1989 79 83
8. L.M. Russo, and S.A. Webber Pediatric heart transplantation: immunosuppression and its complications Curr Opin Cardiol 19 2004 104 109
9. K.A. Ford, C.M. Cale, P.G. Rees, M.J. Elliot, and M. Burch Initial data on Basiliximab in critically ill children undergoing heart transplantation J Heart Lung Transplant 24 2005 1284 1288
10. M.M. Sarwal, P.D. Yorgin, and S. Alexander Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation Transplantation 72 2001 13 21
11. T.P. Singh, C. Faber, and E.D. Blume Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients J Heart Lung Transplant 29 2010 517 522
12. P.S. Macdonald, J. Mundy, A.M. Keogh, V.P. Chang, and P.M. Spratt A prospective, randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantationincreased mortality with OKT3 Transplantation 55 1993 110 116
13. J.K. Kirklin, R.C. Bourge, and C. White-Williams Prophylactic therapy for rejection after cardiac transplantation: a comparison of rabbit antithymocyte globulin and OKT3 J Thorac Cardiovasc Surg 99 1990 716 724
14. M.R. Johnson, G.M. Mullen, and E.J. O'Sullivan Risk/benefit ratio of perioperative OKT3 in cardiac transplantation Am J Cardiol 74 1994 261 266
15. L.J. Swinnen, M.R. Costanzo-Nordin, and S.G. Fisher Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients N Engl J Med 323 1990 1723 1728
16. R.J. Faull, P. Hollett, and S.P. McDonald Lymphoproliferative disease after renal transplant in Australia and New Zealand Transplantation 80 2005 193 197
17. G. Mourad, L. Rostaing, C. Legendre, V. Garrigue, E. Thervet, and D. Durand Sequential protocols using basiliximab versus antithymocyte globulins in renal transplant patients receiving Mycophenolate Mofetil and steroids Transplantation 78 2004 584 590
18. R. Adamson, E. Obispo, and S. Dychter Long-term outcome with use of OKT3 induction therapy in heart transplant patientsa single center experience Transplant Proc 30 1998 1107 1109
19. D.O. Taylor, L.B. Edwards, and P. Aurora Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report2008 J Heart Lung Transplant 27 2008 943 956
20. D. Bernstein, D. Baum, and G. Berry Neoplastic disorders after pediatric heart transplantation Circulation 88 1993 230 237
21. R.E. Shaddy, E.A. Bullock, and N.J. Morwessel Murine monoclonal CD3 antibody (OKT3)-based early rejection prophylaxis in pediatric heart transplantation J Heart Lung Transplant 12 1993 434 439
22. C.E. Canter, S. Moorhead, and J.E. Saffitz Steroid withdrawal in the pediatric heart transplant recipient initially treated with triple immunosuppression J Heart Lung Transplant 13 1994 74 80
23. N.L. Harris, S.H. Swerdlow, G. Frizzera, and D.M. Knowles Post-transplant lymphoproliferative disorders E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman, Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001 IARC Press Lyon 264 269
24. M. Green, and S.A. Webber Posttransplantation lymphoproliferative disorders Pediatr Clin N Am 50 2003 1471 1491
25. S.A. Webber, D.C. Naftel, F.J. Fricker PHTS Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study Lancet 367 2006 233 239
26. G. Opelz, and R. Henderson Incidence of non-Hodgkin's lymphoma in kidney and heart transplant recipients Lancet 342 1993 1514 1516
27. M.A. Hook, C.S. Wade, and W.J. Millikan Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation Pharmacotherapy 11 1991 26 37
28. N. Bonnefoy-Bernard, and J.P. Revillard Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3 J Heart Lung Transplant 15 1996 435 442
29. S.D. Zangwill, D.T. Hsu, and M.R. Kichuk Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients J Heart Lung Transplant 17 1998 1161 1166
30. M.A. Bingler, B. Feingold, and S.A. Miller Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children Am J Transplant 8 2008 442 445
31. A.D. Kirk, W.S. Cherikh, and M. Ring Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab Am J Transplant 7 2007 2619 2625
32. S. Vignot, S. Faivre, D. Aquirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 2005 525 537
33. J.G. Gossett, C.E. Canter, and J. Zheng Decline in rejection in the first year after pediatric cardiac transplantation: a multi-institutional study J Heart Lung Transplant 29 2010 625 632
34. J.O. O'Neill, L.B. Edwards, and D.O. Taylor Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society of Heart and Lung Transplantation J Heart Lung Transplant 25 2006 1186 1191
35. A. Keogh Long-term benefits of mycophenolate mofetil after heart transplantation Transplantation 70 2000 94 99
36. C. Manlhiot, S. Pollock-BarZiv, and C. Holmes Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients J Heart Lung Transplant 29 2010 648 657
37. F. Flaman, S. Zieroth, V. Rao, H. Ross, and D. Delgado Basiliximab versus rabbit antithymocyte globulin for induction therapy in patients after heart transplantation J Heart Lung Transplant 25 2006 1358 1362
38. R.E. Hershberger, R.C. Starling, and H.J. Eisen Daclizumab to prevent rejection after cardiac transplantation N Engl J Med 352 2005 2705 2715
39. J. Segovia, J.L. Rodriguez-Lambert, and M.G. Crespo-Leiro A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study Transplantation 81 2006 1542 1548
40. M.F. Mattei, M. Redonnet, and I. Gandjbakhch Lower risk of infectious deaths in cardiac transplant patients receiving Basiliximab versus antithymocyte globulin therapy J Heart Lung Transplant 26 2007 693 699
41. F.W. Smart, D.C. Naftel, and M.R. Constanzo Risk factors for early, cumulative and fatal infections after a heart transplantation: a multi-institutional study J Heart Lung Transplant 15 1996 329 341
42. P. Grossi, R. DeMaria, A. Caroli, M.S. Zaina, and L. Minoli Infections in heart transplant recipients: the experience of the Italian Heart Transplant Program J Heart Lung Transplant 11 1992 847 866
43. R.A. Frank, J.A. Sanchez, L.J. Addonizio, D.T. Hsu, E.A. Rose, and R.E. Micher OKT3 induction therapy increases early infections and does not reduce early rejections in pediatric heart transplantation J Heart Lung Transplant 10 1991 161
44. T.F. Muller, S.O. Grebe, and C. Neuman Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies Transplantation 64 1997 1432 1437